Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.
April 02, 2024
Share
Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024. These Common Stock will be under lockup for 61 days starting from 2-FEB-2024 to 3-APR-2024.
Details:
The officers and directors have agreed to a ?lock-up? with respect to shares of our common stock and other securities beneficially owned, including securities that are convertible into, or exchangeable or exercisable for, shares of our common stock for a period ending 60 days after the closing of this offering
Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.